NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $12.79 -0.30 (-2.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.55▼$12.9850-Day Range$10.19▼$18.4852-Week Range$9.14▼$24.11Volume1.49 million shsAverage Volume232,962 shsMarket Capitalization$1.76 billionP/E Ratio1,279.00Dividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside79.8% Upside$23.00 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 18 Articles This WeekInsider TradingN/AProj. Earnings Growth21.59%From $1.76 to $2.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector326th out of 936 stocksPharmaceutical Preparations Industry151st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently increased by 532.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 3.0 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Indivior this week, compared to 2 articles on an average week.Search Interest3 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to grow by 21.59% in the coming year, from $1.76 to $2.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 1,279.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 1,279.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 172.24.Price to Book Value per Share RatioIndivior has a P/B Ratio of 34.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Indivior's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Indivior Stock (NASDAQ:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesJuly 26 at 4:15 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INDVJuly 26 at 8:40 AM | seekingalpha.comIndivior: End Of Legal Challenges In SightJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 24 at 7:38 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INDVJuly 24 at 12:29 PM | americanbankingnews.comIndivior (INDV) to Release Quarterly Earnings on ThursdayJuly 23 at 7:12 AM | americanbankingnews.comIndivior (NASDAQ:INDV) Coverage Initiated by Analysts at Piper SandlerJuly 22, 2024 | globenewswire.comIndivior PLC (INDV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INDVJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Indivior PLC - INDVJuly 18, 2024 | americanbankingnews.comIndivior (NASDAQ:INDV) Sees Strong Trading VolumeJuly 16, 2024 | globenewswire.comIndivior PLC (INDV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 10, 2024 | globenewswire.comIndivior PLC (INDV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 10, 2024 | proactiveinvestors.comIndivior share price steadies as drug maker finds a friend in the CityJuly 9, 2024 | globenewswire.comINDV Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Indivior PLC for Potential Securities Law ViolationsJuly 9, 2024 | seekingalpha.comIndivior PLC (INDV) Business Update Call TranscriptJuly 9, 2024 | investorplace.comWhy Is Indivior (INDV) Stock Down 37% Today?June 18, 2024 | prnewswire.comIndivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac ArrestSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today7/26/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,164Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$24.00 Low Stock Price Target$22.00 Potential Upside/Downside+79.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,279.00 Forward P/E Ratio7.27 P/E GrowthN/ANet Income$2 million Net Margins0.44% Pretax Margin0.53% Return on Equity842.72% Return on Assets12.42% Debt Debt-to-Equity Ratio23.50 Current Ratio0.92 Quick Ratio0.74 Sales & Book Value Annual Sales$1.09 billion Price / Sales1.61 Cash Flow$2.14 per share Price / Cash Flow5.98 Book Value$0.37 per share Price / Book34.57Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap$1.76 billion OptionableNot Optionable Beta0.69 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXBlueprint MedicinesNASDAQ:BPMCJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANCytokineticsNASDAQ:CYTKView All CompetitorsInstitutional OwnershipLiontrust Investment Partners LLPSold 8,617 shares on 7/26/2024Ownership: 0.993%Bank of New York Mellon CorpBought 11,672 shares on 7/26/2024Ownership: 0.008%Artemis Investment Management LLPSold 824,681 shares on 7/15/2024Ownership: 0.116%Janus Henderson Group PLCBought 54,750 shares on 5/16/2024Ownership: 0.319%FourWorld Capital Management LLCBought 103,394 shares on 5/16/2024Ownership: 0.075%View All Institutional Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $15.27 at the beginning of the year. Since then, INDV stock has decreased by 16.2% and is now trading at $12.79. View the best growth stocks for 2024 here. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) announced its earnings results on Thursday, February, 22nd. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.15. The firm had revenue of $293 million for the quarter, compared to the consensus estimate of $260 million. Indivior had a net margin of 0.44% and a trailing twelve-month return on equity of 842.72%. Who are Indivior's major shareholders? Top institutional investors of Indivior include Liontrust Investment Partners LLP (0.99%), Artemis Investment Management LLP (0.12%) and Bank of New York Mellon Corp (0.01%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDV Stock Alerts